Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, has announced plans to advance its investigational drugs SION-719 and SION-451 to the next stage of clinical development. SION-719 will be evaluated in a Phase 2a proof-of-concept trial as an add-on to the standard of care in cystic fibrosis patients. Additionally, SION-451 will undergo a Phase 1 trial in healthy volunteers, testing dual combinations with SION-2222 and SION-109. Both trials are set to commence in the second half of 2025, with data expected by mid-2026. Preclinical data demonstrating the potential of these dual combinations to achieve full CFTR correction in CF models were presented at the 48th European Cystic Fibrosis Conference.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。